Publications by authors named "Mark A Davis-Lorton"
Background: Hereditary angioedema (HAE) is a rare genetic disorder with substantial morbidity and mortality. Despite expanded choices for effective acute treatment, prophylactic options are more limited. Intravenous C1 esterase inhibitor (C1-INH[IV]) is licensed and used to prevent HAE symptoms.
View Article and Find Full Text PDFBackground: Nanofiltered C1 inhibitor (human) is approved in the United States for routine prophylaxis of angioedema attacks in patients with hereditary angioedema, a rare disease caused by a deficiency of functional C1 inhibitor.
Objective: To assess the safety of escalating doses of nanofiltered C1 inhibitor (human) in patients who were not adequately controlled on the indicated dose (1000 U every 3 or 4 days).
Methods: Eligible patients had >1 attack/month over the 3 months before the trial.
Article Synopsis
- Hereditary angioedema (HAE) is caused by mutations in the C1 INH gene, leading to unpredictable and potentially life-threatening swelling due to bradykinin.
- Treatment for HAE can involve medications for acute episodes and prophylaxis, with a focus on individualizing care based on the patient's specific needs and situation.
- Approved prophylactic options include attenuated androgens and various forms of C1 INH, while alternative therapies like fresh frozen plasma may be used, though they come with potential side effects.
Objectives: Using serum neopterin as a marker of macrophage activation, we sought to examine the relationship between serum neopterin levels, thrombolysis in myocardial infarction (TIMI) risk scores, and how different treatments of acute coronary syndromes affect change in neopterin.
Methods: We examined serum neopterin concentrations at presentation and 72 h after treatment in 70 patients with acute coronary syndromes (35 with medical therapy, 25 with uncoated coronary stents, and 10 received rapamycin-eluting stents) using a commercially available immunoassay. Serum neopterin levels were determined for 36 patients with stable coronary artery disease.